Onyx raising $358M; Alnylam plots $125M offering;

Conversations on Twitter :

 @FierceBiotech: Takeda's R&D boss infuses 'urgency' into Japan's No. 1 drugmaker. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Buzz: AstraZeneca reorganization inspires fresh rumors of Shire bid. Story | Follow @JohnCFierce

@RyanMFierce: Pharma fumbles in recruitment game as clinical trials miss goals. Article | Follow @RyanMFierce

> Onyx Pharmaceuticals ($ONXX) is selling $358 million in stock to fund its rollout of Kyprolis as well as R&D work. And with that kind of money in play, there's been some speculation on Twitter today that the biotech may be getting ready to do a deal of some kind. Report

> The RNAi player Alnylam ($ALNY) is raising $125 million in a new stock offering. Release

> The Cambridge,MA-based startup Moderna Therapeutics named Divakar Ramakrishnan, Ph.D., is as senior vice president of process development, manufacturing and quality. Release

> Troubled Tranzyme, which has reported two recent trial failures, has named David Moore as its new business development chief. Report

> Galapagos earned a 4 million euro milestone payment from partner Janssen for delivering a preclinical compound as part of the two companies alliance. Release

Medical Device News

 @FierceMedDev: Quest takes $89.5M hit as it plots sale of Dx products unit. Report | Follow @FierceMedDev

@MarkHFierce: SV Bio says it is trying simplify gene sequencing for every day Dx purposes . System should be ready for market soon. Report | Follow @MarkHFierce

 @DamianFierce: And, finally, $COV has a renal denervation device on the market overseas. Story | Follow @DamianFierce

> Luminex grabs FDA clearance for stomach bug diagnostic. News

> Illumina keeps pursuing buys, but remains willing to be acquired. Item

Pharma News

@FiercePharma: Pfizer settles bellwether Chantix case ahead of next week's trial date. Amount undisclosed. More | Follow @FiercePharma

 @AlisonBFierce: WHO says dengue is the world's fastest-spreading tropical disease. GSK's dengue vaccine flopped in trials last year. News | Follow @AlisonBFierce

> EU signs off on Lilly's Amyvid, its diagnostic test for Alzheimer's. Story

> AZ enlists U.K. minister to help boost Brilique use. More

Drug Delivery News

> Pfizer launches first U.S. once-daily liquid ADHD drug. Article

> Clearside plans to move microinjections into clinic. Report

> BioTime seeks EU support for stem cell delivery gel. Story

> Aussie nanopatch offers new way to vaccinate. Item

> Bayer's extended use IUD nets FDA go-ahead. News

And Finally… Investigators at the University of Missouri say they've created a new micro-dystrophin gene therapy that effectively treated Duchenne muscular dystrophy in dogs. Release

 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.